The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from Business Wire

Illumina Introduces Nextera® XT DNA Sample Preparation Kits

<p class='bwalignc'> <i>The fastest, most cost-effective sample preparation and sequencing workflow for small genomes, amplicons, and plasmids with the MiSeq® System</i> </p>

Thursday, May 31, 2012

Illumina Introduces Nextera® XT DNA Sample Preparation Kits06:30 EDT Thursday, May 31, 2012 SAN DIEGO (Business Wire) -- Illumina (NASDAQ:ILMN) today introduced the Nextera XT DNA Sample Preparation Kit, the easiest way for researchers to prepare and sequence small genomes, PCR amplicons, and plasmids. When paired with Illumina's MiSeq system, Nextera XT provides the fastest time to result of any next-generation sequencing technology currently available, enabling researchers to go from genomic DNA to analyzed data in less than 8 hours. Nextera is the industry's fastest sequencing sample preparation technology, with a simple assay that fragments DNA and inserts sequencing adapters and barcodes, all in a single tube. Nextera XT builds on this foundation with its cost-effective and improved workflow. The kit's innovative sample normalization procedure eliminates the need for library quantitation prior to sample pooling and sequencing. “Whether you are sequencing bacterial or viral genomes, plasmids, or PCR amplicons, the Nextera XT DNA Sample Preparation kit delivers the fastest time to answer,” said Christian Henry, Senior Vice President and General Manager of Illumina's Genomic Solutions Business. “Researchers will easily and cost-effectively be able to prepare a large number of amplicons by simultaneously pooling and preparing them with Nextera XT. Up to 96 samples can then be combined and rapidly sequenced to enable flexible and scalable study design.” Additionally, Nextera XT DNA Sample Preparation Kits offer unique benefits to researchers including: Support for both the MiSeq and HiSeq® sequencing platforms Integrated barcodes to support up to 96 samples per MiSeq run; up to 1,536 samples per HiSeq 2000 run; and, up to 384 samples per HiSeq 2500 run in rapid run mode A 90-minute total sample preparation workflow, with the ability to manually process up to 900 samples per week “Nextera XT made transitioning our targeted HIV amplicon sequencing experiments to the MiSeq system extremely easy,” said Dr. Jacques Corbeil from the Infectious Disease Research Center in Quebec and Canada Research Chair in Medical Genomics. “The output of the MiSeq system helps us screen many more samples rapidly, and its high-quality data enables us to detect low-frequency HIV variants.” Illumina's Nextera XT DNA Sample Preparation Kits are now shipping. For more information, visit www.illumina.com/xt. About Illumina Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare. Forward-Looking Statements This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release. Illumina, Inc.Investors:Kevin Williams, MDInvestor Relations858-332-4989kwilliams@illumina.comorMedia:Jennifer TemplePublic Relations858-429-8350pr@illumina.com